Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2011

01-04-2011 | Commentary

Per-arnt-sim (PAS) domain kinase (PASK) as a regulator of glucagon secretion

Authors: P. E. MacDonald, P. Rorsman

Published in: Diabetologia | Issue 4/2011

Login to get access

Abstract

The physiological and pathophysiological regulation of glucagon secretion from pancreatic alpha cells remains a hotly debated topic. The mechanism(s) contributing to the glucose sensitivity of glucagon release and its impaired regulation in diabetes remain unclear. A paper in the current issue of Diabetologia by da Silva Xavier and colleagues (doi:10.​1007/​s00125-010-2010-7) provides intriguing new insight into a metabolic sensing pathway mediated by the per-arnt-sim (PAS) domain kinase (PASK) that may contribute to both the paracrine and the intrinsic glucose regulation of alpha cells. Importantly, the authors show that PASK is decreased in islets from patients with type 2 diabetes, providing a potential mechanism for impaired suppression of glucagon by hyperglycaemia in this disease. Much work remains to be done to determine the exact role and mechanism of PASK in alpha and beta cells. Nevertheless, the present work introduces a new player in the metabolic regulation of glucagon secretion.
Literature
1.
Dobbs R, Sakurai H, Sasaki H et al (1975) Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187:544–547PubMedCrossRef
2.
Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837–848PubMedCrossRef
3.
Aguilar-Parada E, Eisentraut AM, Unger RH (1969) Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci 257:415–419PubMedCrossRef
4.
Ali S, Drucker DJ (2009) Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 296:E415–E421PubMedCrossRef
5.
Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ (2010) The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59:1765–1770PubMedCrossRef
6.
Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116PubMedCrossRef
7.
Barg S, Galvanovskis J, Gopel SO, Rorsman P, Eliasson L (2000) Tight coupling between electrical activity and exocytosis in mouse glucagon-secreting alpha-cells. Diabetes 49:1500–1510PubMedCrossRef
8.
Gopel SO, Kanno T, Barg S, Weng XG, Gromada J, Rorsman P (2000) Regulation of glucagon release in mouse α-cells by KATP channels and inactivation of TTX-sensitive Na+ channels. J Physiol 528:509–520PubMedCrossRef
9.
MacDonald PE, de Marinis YZ, Ramracheya R et al (2007) A KATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol 5:e143PubMedCrossRef
10.
Spigelman AF, Dai X, MacDonald PE (2010) Voltage-dependent K+ channels are positive regulators of alpha cell action potential generation and glucagon secretion in mice and humans. Diabetologia 53:1917–1926PubMedCrossRef
11.
da Silva Xavier G, Farhan H, Kim H et al (2010) Per-arnt-sim (PAS) domain-containing protein kinase is downregulated in human islets in type 2 diabetes and regulates glucagon secretion. Diabetologia. doi:10.​1007/​s00125-010-2010-7
12.
da Silva XG, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA (2003) Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J 371:761–774CrossRef
13.
Tsuboi T, da Silva XG, Leclerc I, Rutter GA (2003) 5′-AMP-activated protein kinase controls insulin-containing secretory vesicle dynamics. J Biol Chem 278:52042–52051PubMedCrossRef
14.
Targonsky ED, Dai F, Koshkin V et al (2006) Alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Diabetologia 49:1587–1598PubMedCrossRef
15.
Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15–25PubMedCrossRef
16.
McDonald A, Fogarty S, Leclerc I, Hill EV, Hardie DG, Rutter GA (2009) Control of insulin granule dynamics by AMPK dependent KLC1 phosphorylation. Islets 1:198–209PubMedCrossRef
17.
Leclerc I, Sun G, Morris C, Fernandez-Millan E, Nyirenda M, Rutter GA (2010) AMP-activated protein kinase regulates glucagon secretion from mouse pancreatic alpha cells. Diabetologia 54:125–134PubMedCrossRef
18.
Schlafli P, Borter E, Spielmann P, Wenger RH (2009) The PAS-domain kinase PASKIN: a new sensor in energy homeostasis. Cell Mol Life Sci 66:876–883PubMedCrossRef
19.
da Silva XG, Rutter J, Rutter GA (2004) Involvement of Per-Arnt-Sim (PAS) kinase in the stimulation of preproinsulin and pancreatic duodenum homeobox 1 gene expression by glucose. Proc Natl Acad Sci U S A 101:8319–8324CrossRef
20.
Fontes G, Semache M, Hagman DK et al (2009) Involvement of Per-Arnt-Sim kinase and extracellular-regulated kinases-1/2 in palmitate inhibition of insulin gene expression in pancreatic beta-cells. Diabetes 58:2048–2058PubMedCrossRef
21.
Hao HX, Cardon CM, Swiatek W et al (2007) PAS kinase is required for normal cellular energy balance. Proc Natl Acad Sci U S A 104:15466–15471PubMedCrossRef
22.
Borter E, Niessen M, Zuellig R et al (2007) Glucose-stimulated insulin production in mice deficient for the PAS kinase PASKIN. Diabetes 56:113–117PubMedCrossRef
23.
Rorsman P, Salehi SA, Abdulkader F, Braun M, Macdonald PE (2008) KATP-channels and glucose-regulated glucagon secretion. Trends Endocrinol Metab 19:277–284PubMedCrossRef
24.
Light PE, Wallace CH, Dyck JR (2003) Constitutively active adenosine monophosphate-activated protein kinase regulates voltage-gated sodium channels in ventricular myocytes. Circulation 107:1962–1965PubMedCrossRef
25.
Wang CZ, Wang Y, Di A et al (2005) 5-Amino-imidazole carboxamide riboside acutely potentiates glucose-stimulated insulin secretion from mouse pancreatic islets by KATP channel-dependent and -independent pathways. Biochem Biophys Res Commun 330:1073–1079PubMedCrossRef
26.
Alzamora R, Gong F, Rondanino C et al (2010) AMP-activated protein kinase inhibits KCNQ1 channels through regulation of the ubiquitin ligase Nedd4-2 in renal epithelial cells. Am J Physiol Renal Physiol 299:F1308–F1319
27.
Evans AM, Hardie DG, Peers C et al (2009) Ion channel regulation by AMPK: the route of hypoxia-response coupling in the carotid body and pulmonary artery. Ann N Y Acad Sci 1177:89–100PubMedCrossRef
28.
Dallas ML, Scragg JL, Wyatt CN et al (2009) Modulation of O2 sensitive K+ channels by AMP-activated protein kinase. Adv Exp Med Biol 648:57–63PubMedCrossRef
29.
Ramracheya R, Ward C, Shigeto M et al (2010) Membrane potential-dependent inactivation of voltage-gated ion channels in alpha-cells inhibits glucagon secretion from human islets. Diabetes 59:2198–2208PubMedCrossRef
30.
Dunning BE, Foley JE, Ahren B (2005) Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48:1700–1713PubMedCrossRef
Metadata
Title
Per-arnt-sim (PAS) domain kinase (PASK) as a regulator of glucagon secretion
Authors
P. E. MacDonald
P. Rorsman
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2072-1

Other articles of this Issue 4/2011

Diabetologia 4/2011 Go to the issue

Article

Paracrine signalling loops in adult human and mouse pancreatic islets: netrins modulate beta cell apoptosis signalling via dependence receptors

Erratum

Erratum to: Association of glucose metabolism with diastolic function along the diabetic continuum

Commentary

Stressed hearts in children with obesity and diabetes: a cause for concern?

Article

Glucose metabolism-related protein 1 (GMRP1) regulates pancreatic beta cell proliferation and apoptosis via activation of Akt signalling pathway in rats and mice

Short Communication

Cumulative glycaemia as measured by lens fluorometry: association with retinopathy in type 2 diabetes

Article

Leptin downregulates expression of the gene encoding glucagon in alphaTC1-9 cells and mouse islets
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits